Listen up 👂
It's hard to over-hype this paper from Michelle Monje and Crystal Mackall on cellular therapy for #DIPG, a fatal childhood brain cancer.
It's not a perfect therapy; doesn't always work. By goodness, what progress we are making!
#CanSky
#MEDsky
#PedCanSky
www.nature.com/articles/s41...
It's hard to over-hype this paper from Michelle Monje and Crystal Mackall on cellular therapy for #DIPG, a fatal childhood brain cancer.
It's not a perfect therapy; doesn't always work. By goodness, what progress we are making!
#CanSky
#MEDsky
#PedCanSky
www.nature.com/articles/s41...
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas - Nature
We evaluated the use of chimeric antigen receptor-modified T cells targeting GD2 (GD2-CART) for H3K27M+ diffuse midline glioma (DMG), finding that intravenous administration of GD2-CART, followed by i...
www.nature.com
November 14, 2024 at 2:04 AM
Listen up 👂
It's hard to over-hype this paper from Michelle Monje and Crystal Mackall on cellular therapy for #DIPG, a fatal childhood brain cancer.
It's not a perfect therapy; doesn't always work. By goodness, what progress we are making!
#CanSky
#MEDsky
#PedCanSky
www.nature.com/articles/s41...
It's hard to over-hype this paper from Michelle Monje and Crystal Mackall on cellular therapy for #DIPG, a fatal childhood brain cancer.
It's not a perfect therapy; doesn't always work. By goodness, what progress we are making!
#CanSky
#MEDsky
#PedCanSky
www.nature.com/articles/s41...